Cure8 news brief
This mid-stage trial suggests a dual-targeting combo may improve endoscopic remission rates in Crohn’s disease compared with IL-23 inhibition alone, which could influence future treatment options and company strategies for IBD therapies.
Adults with Crohn’s disease, patients currently on or considering biologic therapy (especially IL-23 inhibitors), IBD clinicians, and researchers focused on combination biologic strategies or immune pathways in IBD.
AbbVie reported Phase 2a TARGET-CD results showing ABBV-466 (a combination of Skyrizi [an IL-23 p19 inhibitor] and trosunilimab [an anti-α4β7 integrin antibody]) met the trial primary endpoint with higher endoscopic remission rates than either monotherapy at weeks 12 and 24.
Serious adverse event rates were slightly higher in the combo arm (10.4%) versus Skyrizi (9.6%) and trosunilimab (9%). Results were presented as a late-breaker at UEGW 2026 and summarized in an AbbVie press release and analyst commentary.
These are Phase 2a results presented at a conference and reported by AbbVie; longer follow-up, larger Phase 3 trials, and independent peer-reviewed publication will be needed to confirm efficacy and safety. The article summarizes company data and analyst reaction rather than a full peer-reviewed report.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...
Researchers are testing whether blocking three inflammation pathways at once can reduce tissue inflammation more than single drugs. If ex vivo results show stronger effects, it could guide development of multi-target...
